X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-09-15 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $24.19 | -189 | 53,468 | 0% | -$4,572 | ||||||
2025-09-16 | MNKD | Mannkind Corp | Tross Stuart A | Chief People, Workpl Officer | S - Sale | $5.34 | -47,000 | 1,032,013 | -4% | -$250,980 | ||||||
| D | 2025-09-16 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $114.48 | -45,783 | 0 | -100% | -$5,241,127 | |||||
2025-09-16 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $7.04 | -363,541 | 14,363,975 | -2% | -$2,559,329 | ||||||
2025-09-15 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $23.70 | +660 | 6,829,524 | 0% | +$15,639 | ||||||
2025-09-17 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $2.02 | +2,500 | 1,140,937 | 0% | +$5,050 | ||||||
2025-09-16 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $1.97 | +2,600 | 585,644 | 0% | +$5,122 | ||||||
| D | 2025-09-15 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | GC | S - Sale+OE | $11.49 | -15,829 | 0 | -100% | -$181,875 | |||||
| D | 2025-09-15 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $36.46 | -16,400 | 34,552 | -32% | -$597,976 | |||||
| D | 2025-09-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $79.08 | -27,000 | 249,062 | -10% | -$2,135,055 | |||||
| D | 2025-09-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $400.27 | -4,000 | 644,489 | -1% | -$1,601,062 | |||||
| D | 2025-09-15 | LQDA | Liquidia Corp | Singh Raman | Dir | S - Sale+OE | $25.81 | -45,524 | 31,255 | -59% | -$1,174,974 | |||||
2025-09-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $24.19 | -8,500 | 418,142 | -2% | -$205,649 | ||||||
| D | 2025-09-15 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale+OE | $41.41 | -15,000 | 97,130 | -13% | -$621,143 | |||||
| D | 2025-09-15 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale+OE | $45.41 | -1,542 | 38,867 | -4% | -$70,022 | |||||
2025-09-15 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $2.68 | +3,400 | 1,061,237 | 0% | +$9,105 | ||||||
| D | 2025-09-15 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $400.56 | -22,500 | 2,648 | -89% | -$9,012,624 | |||||
| D | 2025-09-12 | CRMD | Cormedix Inc. | Dunton Alan W | Dir | S - Sale+OE | $13.13 | -10,000 | 40,250 | -20% | -$131,300 | |||||
| M | 2025-09-12 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.85 | -4,110 | 4,379,743 | 0% | -$7,603 | |||||
| DM | 2025-09-12 | AXSM | Axsome Therapeutics, Inc. | Tabuteau Herriot | CEO, 10% | S - Sale+OE | $117.08 | -62,880 | 7,351,729 | -1% | -$7,361,891 | |||||
2025-09-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale | $36.00 | -11,367 | 81,524 | -12% | -$409,266 | ||||||
2025-09-16 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale | $21.40 | -8,172 | 197,394 | -4% | -$174,846 | ||||||
| D | 2025-09-12 | LBRX | Lb Pharmaceuticals Inc | Deep Track Biotechnology Master Fund, Ltd. | 10% | P - Purchase | $15.00 | +2,666,666 | 3,352,804 | +389% | +$39,999,990 | |||||
2025-09-12 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $30.00 | -15,000 | 232,122 | -6% | -$450,000 | ||||||
2025-09-15 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale | $23.65 | -3,498 | 43,447 | -7% | -$82,728 | ||||||
| D | 2025-09-11 | PTCT | Ptc Therapeutics, Inc. | Reeve Emma | Dir | S - Sale+OE | $59.50 | -15,705 | 10,332 | -60% | -$934,448 | |||||
| D | 2025-09-12 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $64.58 | -1,700 | 57,130 | -3% | -$109,787 | |||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $6.43 | -1,257 | 84,046 | -1% | -$8,083 | ||||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Mano Michael | SVP, GC, Secretary | S - Sale | $6.43 | -234 | 21,425 | -1% | -$1,505 | ||||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $6.43 | -401 | 27,710 | -1% | -$2,578 | ||||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $6.43 | -408 | 29,390 | -1% | -$2,623 | ||||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Cheng Sohanya Roshan | EVP, Chief Commercial Officer | S - Sale | $6.43 | -325 | 35,856 | -1% | -$2,090 | ||||||
2025-09-15 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $6.43 | -23 | 10,408 | 0% | -$148 | ||||||
2025-09-12 | ZVRA | Zevra Therapeutics, Inc. | Favorito Tamara A | Dir | P - Purchase | $7.79 | +3,175 | 3,894 | +442% | +$24,718 | ||||||
| D | 2025-09-12 | LBRX | Lb Pharmaceuticals Inc | Pontifax Management 4 G.P. (2015) Ltd. | 10% | P - Purchase | $15.00 | +1,000,000 | 1,411,681 | +243% | +$15,000,000 | |||||
| D | 2025-09-12 | LBRX | Lb Pharmaceuticals Inc | Nussbaum Ran | Dir | P - Purchase | $15.00 | +1,000,000 | 1,411,681 | +243% | +$15,000,000 | |||||
| D | 2025-09-12 | LBRX | Lb Pharmaceuticals Inc | Vida Ventures Gp Iii, L.L.C. | 10% | P - Purchase | $15.00 | +333,333 | 883,677 | +61% | +$4,999,995 | |||||
| DM | 2025-09-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $400.93 | -8,000 | 644,489 | -1% | -$3,207,436 | |||||
2025-09-15 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | CEO, 10% | P - Purchase | $9.66 | +10,000 | 3,017,412 | 0% | +$96,624 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | 5Am Partners Vi, LLC | 10% | P - Purchase | $1.53 | +2,941,176 | 5,869,091 | +100% | +$4,499,999 | ||||||
2025-09-12 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $98.42 | -400 | 76,074 | -1% | -$39,368 | ||||||
| D | 2025-09-15 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $21.85 | -6,000 | 110,886 | -5% | -$131,101 | |||||
| D | 2025-09-12 | SUPN | Supernus Pharmaceuticals, Inc. | Mottola Frank | SVP, Chief Tech. Ops. Officer | S - Sale+OE | $45.87 | -5,000 | 15,496 | -24% | -$229,350 | |||||
| DM | 2025-09-11 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $61.18 | -47,249 | 103,901 | -31% | -$2,890,587 | |||||
2025-09-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $49.77 | -5,000 | 377,274 | -1% | -$248,850 | ||||||
| D | 2025-09-12 | MRSN | Mersana Therapeutics, Inc. | Huber Martin H. Jr. | Pres, CEO | S - Sale+OE | $7.31 | -2,012 | 9,572 | -17% | -$14,708 | |||||
| D | 2025-09-12 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $145.45 | -76,520 | 36,461 | -68% | -$11,129,927 | |||||
2025-09-12 | INSM | Insmed Inc | Sharoky Melvin Md | Dir | S - Sale | $145.39 | -10,000 | 294,664 | -3% | -$1,453,900 | ||||||
2025-09-12 | ZVRA | Zevra Therapeutics, Inc. | Shih Alvin | Dir | P - Purchase | $7.89 | +20,000 | 20,000 | New | +$157,800 | ||||||
2025-09-12 | RAPP | Rapport Therapeutics, Inc. | Huber Reid M | Dir | P - Purchase | $24.48 | +20,400 | 20,400 | New | +$499,374 | ||||||
2025-09-12 | RAPP | Rapport Therapeutics, Inc. | Paul Steven M | Dir | P - Purchase | $24.65 | +41,666 | 41,666 | New | +$1,027,111 | ||||||
| D | 2025-09-12 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.44 | -8,706 | 7,614 | -53% | -$56,054 | |||||
| D | 2025-09-12 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.36 | -14,000 | 834,592 | -2% | -$89,048 | |||||
2025-09-12 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $3.12 | +5,000 | 1,057,837 | 0% | +$15,600 | ||||||
| D | 2025-09-12 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | S - Sale+OE | $13.00 | -50,000 | 509,496 | -9% | -$650,000 | |||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $43.02 | -586 | 256,898 | 0% | -$25,210 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $43.02 | -659 | 90,829 | -1% | -$28,350 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $43.02 | -659 | 57,752 | -1% | -$28,350 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $43.02 | -553 | 166,571 | 0% | -$23,790 | ||||||
| DM | 2025-09-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale+OE | $43.23 | -31,796 | 473,902 | -6% | -$1,374,665 | |||||
| M | 2025-09-10 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | CEO, 10% | P - Purchase | $8.03 | +20,000 | 3,007,412 | +1% | +$160,654 | |||||
| D | 2025-09-11 | MIRM | Mirum Pharmaceuticals, Inc. | Brege Laura | Dir | S - Sale+OE | $74.40 | -17,000 | 15,703 | -52% | -$1,264,868 | |||||
| D | 2025-09-12 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $76.01 | -9,578 | 39,945 | -19% | -$728,024 | |||||
2025-09-11 | VTRS | Viatris Inc | Le Goff Corinne | Chief Commercial Officer | S - Sale | $10.25 | -7,032 | 35,299 | -17% | -$72,045 | ||||||
| D | 2025-09-11 | CYRX | Cryoport, Inc. | Hariri Robert J | Dir | S - Sale+OE | $9.71 | -25,000 | 51,275 | -33% | -$242,738 | |||||
2025-09-11 | XERS | Xeris Biopharma Holdings, Inc. | Persky Marla | Dir | S - Sale | $7.72 | -15,500 | 148,370 | -9% | -$119,610 | ||||||
2025-09-10 | PMVP | Pmv Pharmaceuticals, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $1.80 | -500,000 | 5,975,291 | -8% | -$900,000 | ||||||
2025-09-11 | TGTX | Tg Therapeutics, Inc. | Lonial Sagar | Dir | S - Sale | $32.24 | -20,852 | 94,061 | -18% | -$672,268 | ||||||
| D | 2025-09-10 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $325.53 | -10,006 | 237,562 | -4% | -$3,257,289 | |||||
2025-09-10 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | P - Purchase | $28.91 | +10,000 | 86,604 | +13% | +$289,100 | ||||||
| D | 2025-09-10 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $78.83 | -3,725 | 65,963 | -5% | -$293,642 | |||||
2025-09-12 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $31.17 | -2,450 | 73,271 | -3% | -$76,367 | ||||||
| D | 2025-09-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale+OE | $38.94 | -20,000 | 80,195 | -20% | -$778,702 | |||||
2025-09-10 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $26.17 | -20,000 | 183,866 | -10% | -$523,400 | ||||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $3.29 | +121 | 32,942 | 0% | +$398 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $3.29 | +262 | 43,938 | +1% | +$862 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $3.29 | +262 | 5,700,030 | 0% | +$862 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $3.29 | +1,372 | 289,717 | 0% | +$4,516 | |||||
| D | 2025-09-09 | CRMD | Cormedix Inc. | Zelnick Kaufman Beth | GC | S - Sale+OE | $13.41 | -50,000 | 180,418 | -22% | -$670,264 | |||||
| DM | 2025-09-09 | CRMD | Cormedix Inc. | Hurlburt Elizabeth | COO | S - Sale+OE | $13.18 | -53,997 | 176,990 | -23% | -$711,817 | |||||
2025-09-09 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $46.69 | -6,666 | 49,370 | -12% | -$311,214 | ||||||
| M | 2025-09-09 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.59 | -21,120 | 55,200 | -28% | -$857,313 | |||||
| D | 2025-09-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $72.45 | -2,200 | 0 | -100% | -$159,390 | |||||
| M | 2025-09-09 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.94 | -21,046 | 4,383,853 | 0% | -$40,866 | |||||
| DM | 2025-09-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $397.97 | -8,000 | 644,489 | -1% | -$3,183,777 | |||||
| M | 2025-09-10 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $17.69 | +338,394 | 591,831,532 | 0% | +$5,984,756 | |||||
| M | 2025-09-10 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $17.69 | +338,394 | 591,831,532 | 0% | +$5,984,756 | |||||
2025-09-09 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $11.44 | -4,325 | 119,897 | -3% | -$49,460 | ||||||
2025-09-11 | RAPP | Rapport Therapeutics, Inc. | Young Wendy B. | Dir | P - Purchase | $22.60 | +3,500 | 9,500 | +58% | +$79,100 | ||||||
| DM | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Technology, Quality Ofc | S - Sale+OE | $21.00 | -49,792 | 121,503 | -29% | -$1,045,840 | |||||
| DM | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $21.00 | -40,000 | 110,886 | -27% | -$840,102 | |||||
| D | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale+OE | $20.00 | -7,000 | 205,566 | -3% | -$140,000 | |||||
| D | 2025-09-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | CFO, CBO | S - Sale+OE | $35.00 | -20,000 | 0 | -100% | -$700,000 | |||||
2025-09-09 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $350.06 | -5,000 | 1,625,494 | 0% | -$1,750,312 | ||||||
| D | 2025-09-09 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $62.16 | -11,950 | 34,997 | -25% | -$742,838 | |||||
| D | 2025-09-09 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $64.56 | -21,000 | 57,130 | -27% | -$1,355,661 | |||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Polaris Management Co. Vii, L.L.C. | 10% | P - Purchase | $1.53 | +1,307,189 | 1,106,751 | -652% | +$1,999,999 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Nashat Amir | Dir, 10% | P - Purchase | $1.53 | +1,307,189 | 1,106,751 | -652% | +$1,999,999 | ||||||
| D | 2025-09-09 | PTCT | Ptc Therapeutics, Inc. | Southwell David P | Dir | S - Sale+OE | $58.34 | -12,000 | 16,850 | -42% | -$700,080 | |||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Maricich Yuri | Chief Medical Officer | P - Purchase | $1.65 | +6,060 | 6,060 | New | +$9,999 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |